Interactive Workshops

Workshop A: Elevating Psychiatric Preclinical Models: What’s Next?

Wednesday, November 2 | 09:00am - 12:00pm

Despite rapidly advancing technology the world of psychiatric therapeutics remains challenging to navigate. Reduced predictive value of preclinical models presents a roadblock in meaningful drug development that is yet to be fully addressed. Novel therapeutics are required to affect treatment resistant populations and problematic adverse effects and indications. With more companies investing into pipelines to address this large area of unmet need, there has never been a more important time to address drug translation to optimize the chance of clinical success. Attend this impactful, reflective workshop to:

  • Explore the historical landscape of technologies involved in preclinical development to understand the impacts on clinical study
  • Discuss the gap in in vitro and animal models for psychiatric disorders
  • Review the current research and developments in translational models to anticipate implementation into pipeline work
  • Outline the future of preclinical research and opportunities for academic centers and business start-ups to contribute to the field
  • There is likely to be long-term neuropsychiatric morbidity due to stroke, psychiatric disease and long-COVID

Workshop Leaders:

Eric Szelenyi

Eric Szelenyi
Washington Research Foundation
Postdoctoral Fellow
University of Washington

Workshop B: Mapping out Methodologies for Gaining Mechanistic Understanding

Wednesday, November 2 | 1:00pm - 4:00pm

With increasing interest in psychedelic therapeutics and analogues and more pipelines pushing forward to clinical trials, there remains a gap in thorough knowledge of how they affect the brain. From neuroplasticity to dissociation, the actions of these drugs require further exploration in order to develop meaningful treatments that retain the intended effects whilst minimizing adverse activity. This workshop will highlight the methodologies that can be employed to study these mechanisms further, providing reference to data and key examples to advise on how best they can be utilized for individual study.

Attend this session to deep-dive and gain actionable insights in:

  • Utilizing software for deep learning of behavior of rodents for optimal study
  • Translating transcriptome technologies into comprehensive pictures of
    cellular activity
  • Outlining implementation of varied methods to guide drug development
    for optimal effects

Alberto Cruz-Martin
Assistant Professor
Boston University